Free tool
FAERS Monitor: Avgemsi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219920 or its brand name (Avgemsi, Gemcitabine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
40,140
Serious
38,987
97% of reports
Hospitalization
15,169
Death reported
7,548
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression4,646
- thrombocytopenia3,043
- off label use2,910
- drug ineffective2,705
- neutropenia2,703
- anaemia2,483
- malignant neoplasm progression2,153
- nausea2,032
- pyrexia1,978
- fatigue1,707
- diarrhoea1,674
- vomiting1,616
- death1,543
- febrile neutropenia1,407
- dyspnoea1,226
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 486 |
| 2005 | 473 |
| 2006 | 521 |
| 2007 | 344 |
| 2008 | 418 |
| 2009 | 591 |
| 2010 | 452 |
| 2011 | 571 |
| 2012 | 885 |
| 2013 | 800 |
| 2014 | 1,061 |
| 2015 | 1,994 |
| 2016 | 2,392 |
| 2017 | 2,252 |
| 2018 | 2,507 |
| 2019 | 2,656 |
| 2020 | 2,546 |
| 2021 | 2,586 |
| 2022 | 3,132 |
| 2023 | 4,004 |
| 2024 | 3,373 |
| 2025 | 3,434 |
| 2026 | 2,662 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,014,019 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 4,646 | 21.4 | 20.8 | 87,158 |
| thrombocytopeniaSignal | 3,043 | 14.6 | 14.1 | 37,776 |
| febrile neutropeniaSignal | 1,407 | 11.3 | 10.8 | 13,006 |
| malignant neoplasm progressionSignal | 2,153 | 11.2 | 10.8 | 19,730 |
| neutropeniaSignal | 2,703 | 10.6 | 10.2 | 23,194 |
| anaemiaSignal | 2,483 | 6.9 | 6.6 | 12,467 |
| pyrexiaSignal | 1,978 | 3.0 | 2.9 | 2,676 |
| vomiting | 1,616 | 1.8 | 1.7 | 589 |
| off label use | 2,910 | 1.7 | 1.7 | 959 |
| diarrhoea | 1,674 | 1.4 | 1.3 | 164 |
| nausea | 2,032 | 1.3 | 1.3 | 187 |
| fatigue | 1,707 | 1.1 | 1.1 | 34 |
| dyspnoea | 1,226 | 1.1 | 1.1 | 20 |
| drug ineffective | 2,705 | 1.1 | 1.0 | 15 |
| death | 1,543 | 0.9 | 0.9 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.